Trulieve Cannabis (TRLV) Cash & Equivalents (2020 - 2026)

Trulieve Cannabis has reported Cash & Equivalents for 7 years, with the latest figure at $325.4 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 17.11% year-over-year to $325.4 million in Q2 2026; TTM through Jun 2026 was $325.4 million, a 17.11% decrease from a year earlier, with the FY2025 full-year figure at $255.5 million, up 7.01% from the prior year.
• Cash & Equivalents was $325.4 million for Q2 2026 at Trulieve Cannabis, down from $352.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $449.2 million in Q3 2025, with the low at $100.7 million in Q3 2022.
• Average Cash & Equivalents over 5 years is $262.7 million, with a median of $247.2 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents plunged 52.87% in 2022, then soared 133.11% in 2024.
• Over 5 years, Cash & Equivalents stood at $207.2 million in 2022, then dropped by 2.81% to $201.4 million in 2023, then increased by 18.59% to $238.8 million in 2024, then gained by 7.01% to $255.5 million in 2025, then increased by 27.35% to $325.4 million in 2026.
• The last three Cash & Equivalents figures came in at $325.4 million (Q2 2026), $352.9 million (Q1 2026), and $255.5 million (Q4 2025), per Business Quant data.